Two Objective Responses Identified at Interim Analysis With CUE-101 in HPV16+ Recurrent ...

Retrieved on: 2022-02-01 19:05:01

Tags for this article:

Click the tags to see associated articles and topics

Two Objective Responses Identified at Interim Analysis With CUE-101 in HPV16+ Recurrent .... View article details on hiswai:

Excerpt

Drug developer Cue Biopharma intends to file a new drug application for the agent in Q1 of 2022. The IL-2–targeting agent CUE-101 is being ...

Article found on: www.cancernetwork.com